Christopher Viehbacher - Biogen CEO Pres
| BIIB Stock | MXN 3,700 250.00 7.25% |
Insider
Christopher Viehbacher is CEO Pres of Biogen Inc
| Age | 63 |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Barbara Schadler | Roche Holding AG | 61 | |
| Anat Ashkenazi | Eli Lilly and | 51 | |
| Thomas Schinecker | Roche Holding AG | 48 | |
| David Elkins | Bristol Myers Squibb | 55 | |
| Claudia Bockstiegel | Roche Holding AG | 59 | |
| Michael Quigley | Gilead Sciences | N/A | |
| Jacob Naarden | Eli Lilly and | 38 | |
| Peter Dannenbaum | Merck Company | N/A | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Lisa LeCointeCephas | Merck Company | 41 | |
| Johannes MD | Roche Holding AG | 66 | |
| BCH BM | Bristol Myers Squibb | 57 | |
| Cristal Downing | Merck Company | 54 | |
| Anat JD | Eli Lilly and | 54 | |
| Timothy Power | Bristol Myers Squibb | N/A | |
| Martin MIBS | Eli Lilly and | 60 | |
| Linda Higgins | Gilead Sciences | 61 | |
| Cari Gallman | Bristol Myers Squibb | N/A | |
| Donald Zakrowski | Eli Lilly and | N/A | |
| Jyoti Mehra | Gilead Sciences | 47 | |
| Giovanni MD | Bristol Myers Squibb | 58 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO Pres | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Jesus Mantas, Director | ||
| Richard Mulligan, Independent Director | ||
| Paul McKenzie, Executive Vice President - Pharmaceutical Operations & Technology | ||
| Michel Vounatsos, Vice President and Chief Commercial Officer | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Susan Esq, Chief VP | ||
| George Scangos, CEO, Director | ||
| Alfred Sandrock, Executive Vice President - Neurology Discovery and Development and Chief Medical Officer | ||
| Spyros ArtavanisTsakonas, Senior Vice President Chief Scientific Officer | ||
| Alexander Denner, Independent Director | ||
| Natacha Gassenbach, Chief Affairs | ||
| JeanPaul Kress, Executive Vice President and Presidentident - International and Head of Global Therapeutic Operations | ||
| Eric Rowinsky, Independent Director | ||
| William Hawkins, Director | ||
| Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs | ||
| Mark Hernon, Senior Vice President CIO | ||
| Kenneth Pietro, Executive Vice President - Human Resources | ||
| John Chiminski, Director | ||
| Adam Koppel, Executive Vice President - Strategy and Business Development | ||
| Stephen Sherwin, Independent Director | ||
| Caroline Dorsa, Independent Director | ||
| Michael Ehlers, Executive Vice President of Research and Development | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Chirfi Guindo, Executive Vice President Head of Global Marketing, Market Access and Customer Innovation | ||
| Susan Alexander, Executive Vice President Chief Legal Officer and Corporate Secretary | ||
| Catherine Steele, Senior Vice President - Corporate Affairs | ||
| Daniel Karp, Executive Vice President - Corporate Development | ||
| Paul Clancy, CFO, Executive Vice President - Finance | ||
| Steven Holtzman, Executive Vice President - Corporate Development | ||
| Anirvan Ghosh, Senior Vice President - Research and Early Development | ||
| Michael CPA, Ex CFO | ||
| Nancy Leaming, Independent Director | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations | ||
| Lynn Schenk, Independent Director | ||
| Camille Lee, Senior Vice President - Alzheimer's Therapeutic Area | ||
| Brian Posner, Independent Director | ||
| Gregory Covino, Chief Accounting Officer, Vice President - Finance | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Stelios Papadopoulos, Independent Chairman of the Board | ||
| John Cox, Executive Vice President - Global Commercial Operations | ||
| Robert Pangia, Independent Director | ||
| Jeffrey Capello, CFO, Executive Vice President |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 861.61 B | |||
| Shares Outstanding | 144 M | |||
| Shares Owned By Insiders | 0.68 % | |||
| Shares Owned By Institutions | 89.99 % | |||
| Price To Earning | 169.05 X | |||
| Price To Book | 3.30 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biogen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biogen's short interest history, or implied volatility extrapolated from Biogen options trading.
Pair Trading with Biogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.Moving together with Biogen Stock
| 0.89 | ROGN | Roche Holding AG | PairCorr |
| 0.8 | AMGN | Amgen Inc | PairCorr |
Moving against Biogen Stock
| 0.83 | AMZN | Amazon Inc | PairCorr |
| 0.74 | NVDA | NVIDIA | PairCorr |
| 0.5 | BRKB | Berkshire Hathaway | PairCorr |
| 0.47 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |